Time course of changes in 6-sulfatoxymelatonin excretion in patients with breast cancer after various neoadjuvant chemotherapy options

• Main Authors: Yu. S. Sidorenko (Author), O. I. Kit (Author), A. E. Lisutin (Author), O. M. Semiletkin (Author)
• Formato: Livro
• Publicado em: ABV-press, 2014-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The level of the metabolite 6-sulfatoxymelatonin (6-SOM) was studied on automedia before and after neoadjuvant systemic polyche- motherapy and neoadjuvant chemotherapy. Specific therapy was not found to result in normalization of 6-SOM levels, which may be regarded as a poor endogenous factor.